HFE Interpreter: Analyzes C282Y and H63D mutations to determine the risk of clinical iron overload. Note: Clinical penetrance is variable; genotype must be correlated with biochemical iron markers.
C282Y Mutation (p.Cys282Tyr)
H63D Mutation (p.His63Asp)
Guidelines & Evidence
Clinical Details
Section 1
When to Use
Clinical Use
Interpreting HFE gene mutation results in patients with suspected iron overload.
Initial screening when TSAT > 45% or Ferritin is elevated without inflammatory cause.
Section 2
Formula & Logic
HFE Mutations
The HFE gene involved in iron regulation. Mutations lead to low hepcidin levels, resulting in increased dietary iron absorption.
High Risk Genotype
C282Y Homozygosity is responsible for ~90% of clinical Hereditary Hemochromatosis (p.Cys282Tyr).
Compound Heterozygosity
C282Y/H63D is associated with a lower risk of clinical iron overload but can cause elevated biochemical markers.
Section 3
Pearls/Pitfalls
Clinical Penetrance
Genotype does not equal disease. Many homozygous patients never develop clinical symptoms (fatigue, arthropathy, cirrhosis, diabetes).